<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274846</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000450852</org_study_id>
    <secondary_id>UMN-2004LS073</secondary_id>
    <secondary_id>UMN-MT2004-25</secondary_id>
    <nct_id>NCT00274846</nct_id>
  </id_info>
  <brief_title>Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>Allogeneic Natural Killer Cells in Patients With Relapsed Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor peripheral blood stem cell transplant helps
      stop the growth of cancer cells. It also helps stop the patient's immune system from
      rejecting the donor's stem cells. When the healthy stem cells and natural killer (NK) cells
      from a donor are infused into the patient they may help the patient's bone marrow make stem
      cells, red blood cells, white blood cells, and platelets.

      PURPOSE: This clinical trial is studying how well a peripheral stem cell transplant using NK
      cells from a donor works in treating patients with relapsed acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the in vivo expansion of natural killer (NK) cells 14 days after treatment with
           allogeneic NK cell-enriched peripheral blood stem cell transplantation in patients with
           relapsed acute myeloid leukemia.

      Secondary

        -  Determine the response rate, in terms of complete remission, in patients treated with
           this regimen.

        -  Correlate complete remission rate with NK cell expansion, interleukin-15 levels, and
           donor/recipient killer immunoglobulin receptor (KIR) ligand matching status in patients
           treated with this regimen.

        -  Determine the overall and progression-free survival of patients treated with this
           regimen.

        -  Determine the toxicity of this regimen in these patients.

      OUTLINE: This is an open-label study.

        -  Induction therapy: Patients receive fludarabine IV on days -6 to -2 and cyclophosphamide
           IV on day -5 or on days -5 and -4.

        -  Allogeneic natural killer (NK) cell-enriched peripheral blood stem cell transplantation:
           Patients receive allogeneic NK cell-enriched peripheral blood stem cells IV over 15-60
           minutes on day 0. Patients also receive interleukin-2 subcutaneously beginning on day 0
           and continuing 3 times a week for up to 2 weeks.

      After completion of study treatment, patients are followed periodically for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Natural Killer (NK) Cell Expansion</measure>
    <time_frame>Study Day 14</time_frame>
    <description>Evaluation of expansion of donor allogeneic natural killer (NK) cells at day 14 following infusion (&gt;100 donor-derived NK cells per uL of patient blood detectable at day +14).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Complete Remission</measure>
    <time_frame>Day 28-35</time_frame>
    <description>Clinical response is determined by achievement of a complete remission (CR) as judged by morphological criteria (&lt; 1% blasts in bone marrow with neutrophil recovery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Disease Relapse (Months)</measure>
    <time_frame>From 1st Day of treatment until death or receipt of bone marrow transplant.</time_frame>
    <description>Follow-up continued every 3 months after the allogeneic natural killer (NK) cell infusion, unless they were transplanted, relapsed or had progressive disease. Time in months to relapse of disease is calculcated from 1st day of treatment with NK cells. Relapse occurs when leukemia is detected in bone marrow or blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time of Patients With Complete Remission</measure>
    <time_frame>From Day 1 of Treatment until death or patient received bone marrow transplant.</time_frame>
    <description>Median number of months patients were alive after NK cell infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Complete Remission and Natural Killer Cell Expansion</measure>
    <time_frame>Day 14</time_frame>
    <description>Includes patients who had both a complete remission of disease and an expansion of natural killer cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10^7/kg.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses</description>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>Cells infused per kg. 1.5-8.0 x 10^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10^9</description>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <other_name>lymphocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Days -5 and -4: 60 mg/kg</description>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Days -5 through -2: 25 mg/m^2</description>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro treated peripheral blood stem cell transplantation</intervention_name>
    <description>Day 0 infuse natural killer cells</description>
    <arm_group_label>Intent-to-Treat</arm_group_label>
    <other_name>Natural Killer Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:

               -  Primary refractory disease (no complete response [CR] after ≥ 2 induction
                  therapies)

               -  Relapsed disease not in CR after ≥ 1 course of standard reinduction therapy

               -  Secondary AML from myelodysplastic syndromes

               -  Disease relapsed ≥ 2 months after transplant and no option of donor lymphocyte
                  infusions (e.g., recipients of autologous or umbilical cord blood transplants)

               -  Chronic myelogenous leukemia with myeloid blast crisis not in second chronic
                  phase after at least one cycle of standard chemotherapy and imatinib

               -  Over 60 years of age with relapse within 6 months after completion of last
                  chemotherapy

               -  Over 60 years of age with blast count &lt; 30% within 10 days before study entry

          -  Related HLA-haploidentical natural killer cell donor available

          -  No severe organ damage (by clinical or laboratory assessment)

          -  Performance status 50-100%

          -  No evidence of active infection on chest X-ray

          -  No active fungal infection

        Exclusion Criteria:

          -  Active central nervous system (CNS) leukemia

          -  Pleural effusions large enough to be detectable by chest x-ray

          -  Pregnant or nursing (positive pregnancy test)

          -  Fertile patients must use effective contraception

          -  Less than 60 days since prior transplant

          -  Less than 3 days since prior prednisone

          -  Less than 3 days since other prior immunosuppressive medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <results_first_submitted>July 24, 2009</results_first_submitted>
  <results_first_submitted_qc>July 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2009</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With Relapsed/Refractory Acute Myeloid Leukemia</title>
          <description>Patients who met study criteria - relapsed or refractory acute myelogenous leukemia - and were enrolled.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">Evaluable patients - received adequate natural killer (NK) cells</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive adequate NK cells</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Relapsed/Refractory Acute Myeloid Leukemia</title>
          <description>Patients who met study criteria - relapsed or refractory acute myelogenous leukemia - and were enrolled.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Natural Killer (NK) Cell Expansion</title>
        <description>Evaluation of expansion of donor allogeneic natural killer (NK) cells at day 14 following infusion (&gt;100 donor-derived NK cells per uL of patient blood detectable at day +14).</description>
        <time_frame>Study Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Relapsed/Refractory AML - Evaluable Group</title>
            <description>Patients who are evaluable; received adequate (dose of 1.5-8 x 10^7/kg natural killer (NK) cells 14 days after treatment with chemotherapy and allogeneic NK cell-enriched immune therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Natural Killer (NK) Cell Expansion</title>
          <description>Evaluation of expansion of donor allogeneic natural killer (NK) cells at day 14 following infusion (&gt;100 donor-derived NK cells per uL of patient blood detectable at day +14).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Complete Remission</title>
        <description>Clinical response is determined by achievement of a complete remission (CR) as judged by morphological criteria (&lt; 1% blasts in bone marrow with neutrophil recovery).</description>
        <time_frame>Day 28-35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Relapsed/Refractory AML - Evaluable Group</title>
            <description>Patients who are evaluable; received adequate (dose of 1.5-8 x 10^7/kg natural killer (NK) cells 14 days after treatment with chemotherapy and allogeneic NK cell-enriched immune therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complete Remission</title>
          <description>Clinical response is determined by achievement of a complete remission (CR) as judged by morphological criteria (&lt; 1% blasts in bone marrow with neutrophil recovery).</description>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Disease Relapse (Months)</title>
        <description>Follow-up continued every 3 months after the allogeneic natural killer (NK) cell infusion, unless they were transplanted, relapsed or had progressive disease. Time in months to relapse of disease is calculcated from 1st day of treatment with NK cells. Relapse occurs when leukemia is detected in bone marrow or blood.</description>
        <time_frame>From 1st Day of treatment until death or receipt of bone marrow transplant.</time_frame>
        <population>Only 2 of 20 patients that received adequate Natural Killer Cells achieved complete remission, and were therefore evaluable for the time to relapse endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Achieving Complete Remission - Responders</title>
            <description>Patients who achieved complete remission (CR) as judged by morphological criteria; only these patients can be judged for time to relapse.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Disease Relapse (Months)</title>
          <description>Follow-up continued every 3 months after the allogeneic natural killer (NK) cell infusion, unless they were transplanted, relapsed or had progressive disease. Time in months to relapse of disease is calculcated from 1st day of treatment with NK cells. Relapse occurs when leukemia is detected in bone marrow or blood.</description>
          <population>Only 2 of 20 patients that received adequate Natural Killer Cells achieved complete remission, and were therefore evaluable for the time to relapse endpoint.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="3.5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time of Patients With Complete Remission</title>
        <description>Median number of months patients were alive after NK cell infusion.</description>
        <time_frame>From Day 1 of Treatment until death or patient received bone marrow transplant.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Achieving Complete Remission - Responders</title>
            <description>Patients who achieved complete remission (CR) as judged by morphological criteria; only these patients can be judged for time to relapse.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time of Patients With Complete Remission</title>
          <description>Median number of months patients were alive after NK cell infusion.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Complete Remission and Natural Killer Cell Expansion</title>
        <description>Includes patients who had both a complete remission of disease and an expansion of natural killer cells.</description>
        <time_frame>Day 14</time_frame>
        <population>Unable to evaluate due to low complete remission rate.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Relapsed/Refractory AML - Evaluable Group</title>
            <description>Patients who are evaluable; received adequate (dose of 1.5-8 x 10^7/kg natural killer (NK) cells 14 days after treatment with chemotherapy and allogeneic NK cell-enriched immune therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complete Remission and Natural Killer Cell Expansion</title>
          <description>Includes patients who had both a complete remission of disease and an expansion of natural killer cells.</description>
          <population>Unable to evaluate due to low complete remission rate.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events were monitored from Day 1 of study through Day 60 post-natural killer cell infusion.</time_frame>
      <desc>All &quot;other&quot; adverse events that occurred were expected and not captured.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients With Relapsed/Refractory Acute Myeloid Leukemia</title>
          <description>Patients who met study criteria - relapsed or refractory acute myelogenous leukemia - and were enrolled.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <description>central nervous system</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hemorrhage, lung</sub_title>
                <description>pulmonary/upper respiratory-lung</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to progressive disease</sub_title>
                <description>unrelated to study</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Meningitis x2, pneumonia, associated with lymphopenia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <description>radiographic findings</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Miller, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-7409</phone>
      <email>mille011@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

